BioSniper
Phase 3 Readout~month

Phase 3 Topline: Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone F

May 31, 2026
Company
Filana Therapeutics Inc. (FLNA)
Indication
Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma

Other upcoming events for FLNA

Phase 2 StartPhase 2 Start: Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positi
Jul 1, 2026
Phase 2 StartPhase 2 Start: A Multicenter, Open-label, Randomized Controlled Clinical Study Comparing the Efficacy and Safety of
Oct 1, 2026
Phase 3 ReadoutPhase 3 Topline: Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates
Oct 17, 2026
Phase 3 ReadoutPhase 3 Topline: Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Ve
Mar 1, 2027
Phase 3 ReadoutPhase 3 Topline: Non-Steroidal Anti-Inflammatory Drugs Versus Conventional Treatment in Acute Myocarditis (INFLAMA Tr
Oct 1, 2027

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
FLNA OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About
  • Data Methodology

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle